Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBT (2022 - 2025)

CervoMed's EBT history spans 9 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, EBT fell 62.64% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$25.6 million, down 114.15%, while the annual FY2024 figure was -$16.3 million, 114.52% down from the prior year.
  • EBT for Q3 2025 was -$7.7 million at CervoMed, down from -$6.2 million in the prior quarter.
  • Across five years, EBT topped out at -$1.4 million in Q1 2023 and bottomed at -$7.7 million in Q3 2025.
  • The 4-year median for EBT is -$4.2 million (2022), against an average of -$4.0 million.
  • The largest annual shift saw EBT soared 69.27% in 2023 before it crashed 184.05% in 2024.
  • A 4-year view of EBT shows it stood at -$5.9 million in 2022, then soared by 60.12% to -$2.4 million in 2023, then crashed by 184.05% to -$6.7 million in 2024, then decreased by 15.16% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's EBT are -$7.7 million (Q3 2025), -$6.2 million (Q2 2025), and -$4.9 million (Q1 2025).